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The genetic understanding of the muscular dystrophies has advanced considerably in the last two decades. Over 25 different individual genes
are now known to produce muscular dystrophy, and many different “private” mutations have been described for each individual muscular
dystrophy gene. For the more common forms of muscular dystrophy, phenotypic variability can be explained by precise mutations. However, for
many genetic mutations, the presence of the identical mutation is associated with marked phenotypic range that affects muscle function as well as
cardiac function. The explanation for phenotype variability in the muscular dystrophies is only now being explored. The availability of genetically
engineered animal models has allowed the generation of single mutations on the background of highly inbred strain. Phenotypic variation that is
altered by genetic background argues for the presence of genetic modifier loci that can ameliorate or enhance aspects of the dystrophic phenotype.
A number of individual genes have been implicated as modifiers of muscular dystrophy by studies in genetically engineered mouse models of
muscular dystrophy. The value of these genes and products is that the pathways identified through these experiments may be exploited for therapy.
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The muscular dystrophies are heterogeneous, and much of
the variability in disease relates to the precise gene mutation
responsible for disease. Phenotypic variation most commonly
affects factors such as age of onset, timecourse of disease
progression, muscle group involvement, and accompanying
non-muscle features such as cardiac and central nervous system
impairment. Clinical markers such as serum creatine kinase
(CK) may also vary considerably, although for some markers,
like CK, intra-patient variability is present. For patients and
clinicians, identifying the gene responsible for muscularAbbreviations: ADAM, a disintegrin and metalloproteases; BMD, Becker
muscular dystrophy; CK, creatine kinase; CMD, congenital muscular dystrophy;
DMD, Duchenne muscular dystrophy; DGC, dystrophin glycoprotein complex;
EBD, Evans Blue Dye; EDMD, Emery–Dreifuss muscular dystrophy; FKRP,
fukutin related protein; IGF1, insulin like growth factor 1; LGMD, limb girdle
muscular dystrophy; MM, Miyoshi myopathy
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doi:10.1016/j.bbadis.2006.06.013dystrophy is helpful in predicting the onset and pace of disease.
Understanding the precise allele that produces disease is also
predictive of disease course. However, even with the identical
gene mutation, there may be striking variability affecting age of
onset and disease progression. This variation can be seen within
families and suggests that other genetic or environmental factors
can contribute to the manifestation of muscular dystrophy.
Identifying these modifying factors is valuable for designing
therapeutic strategies. Some modifiers are gene specific;
namely, they improve only one genetic form of muscular
dystrophy. Other modifiers may be more broadly applicable and
useful for treating not only all forms of muscular dystrophy, but
may also be useful for treating muscle degeneration in general.
This review will discuss different genetic forms of muscular
dystrophy with an emphasis on phenotypic variability and the
presence of genetic modifiers where they have been identified.
Most modifiers have been discussed in the context of modifying
the phenotype from mutations in the genes encoding dystrophin
or its associated proteins. Modifiers of these forms of muscular
dystrophy may also be effective for other forms of muscular
dystrophy.
Table 1
Phenotypic variability within the LGMD 2C mutation c.525delT
Disease
severity
Creatine
kinase
Age of onset
(years)
α-sg β-sg δ-sg dys References
M ND 9 − − − + [119]
S 25000 4 + + + +++ [13]
S 8 X nl 10 + − − +++ [8]
S 15 X nl 5 + − − +++ [8]
S 11 X nl 5 + − − +++ [8]
M 40 X nl asx + − − +++ [8]
S Elevated 6 ++ +++ +++ +++ [120]
S 8000 9 +++ +++ +++ +++ [121]
α-sg, β-sg, δ-sg and dys refer to the degree of residual staining of these
α-sarcoglycan, β-sarcoglycan, δ-sarcoglycan and dystrophin, respectively. S,
severe; I, intermediate; M, mild; ND, not determined. Asx refers to
asymptomatic relatives with elevated CK but minimal to no weakness at
ages 22 and 23.
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The dystrophin glycoprotein complex (DGC) underlies the
membrane of all muscles (Fig. 1). The DGC provides
mechanical support during muscle contraction and also
contributes nonstructural support in that the DGC modifies
signal transduction [1,2]. Mutations in the dystrophin gene lead
to Duchenne Muscular Dystrophy (DMD) and Becker Muscular
Dystrophy (BMD), and a reasonable genotype–phenotype
correlation has been established for dystrophin gene mutations.
The sarcoglycans are a subcomplex within the larger DGC. The
components of the skeletal and cardiac muscle sarcoglycan
subcomplex are α-, β-, γ- and δ-sarcoglycan, while the
components of the smooth muscle subcomplex are ε-, β-, δ-
and ζ-sarcoglycan [3]. Mutations in the genes encoding the
sarcoglycan subunits result in a subset of the recessively
inherited Limb Girdle Muscular Dystrophies (LGMDs). Muta-
tions in the gene encoding any single sarcoglycan complex
member tend to produce a secondary loss of the nonmutated
sarcoglycan subunits resulting in a loss of the sarcoglycan
subcomplex from the plasma membrane. The presence ofFig. 1. Schematic of the plasma membrane of muscle and nucleus indicating
proteins associated with muscular dystrophy. The dystrophin glycoprotein
complex consists of dystrophin, dystroglycan, the dystrobrevins, syntrophins,
sarcospan, and the sarcoglycan complex. Dysferlin is not associated with the
dystrophin glycoprotein complex. Modifiers that affect the dystrophin
glycoprotein complex include utrophin and integrin α7.residual sarcoglycans does not necessarily correlate with disease
severity (Table 1). The dual roles of the DGC, mechanical
strength and signaling, are evident within the sarcoglycan
subcomplex. Therefore, both of these functions must be
considered when analyzing sarcoglycan-disease causing
mutations.
Mutations in the dysferlin gene lead to LGMD 2B.
Dysferlin mutations often, but not always, are associated
with a loss of dysferlin from the plasma membrane of
muscle. Dysferlin is thought to mediate plasma membrane
repair in muscle since the loss of dysferlin is associated with
defective repair of induced plasma membrane injury [4]. A
considerable range in the degree of muscle weakness is
found with dysferlin mutation indicating the presence of
genetic modifiers.
Mutations that prematurely truncate dystrophin or are
associated with little to no dystrophin protein product typically
are associated with the more severe DMD phenotype [5,6].
Mutations that internally truncate dystrophin but leave intact the
amino and carboxy terminal portions of the protein usually
produce the comparable milder BMD. An inverse correlation
between the residual amount of dystrophin present and disease
progression was noted within a family. At one end was a 15 year
old with severe disease and no detectable dystrophin by
immunofluorescence and western blot, while an affected uncle
had mild disease and positive staining for dystrophin [7]. As the
first gene identified for a muscular dystrophy phenotype, it was
assumed that genotype–phenotype correlation would be
similarly informative for the other inherited muscular dystro-
phies. However, such clear structure–function relationships
have not been evident when considering the range of mutations
in the sarcoglycan genes or in the dysferlin gene. There are
many examples of different mutations within the same protein
causing drastically different diseases.
3. Sarcoglycan
Among the many human sarcoglycan gene mutations, a
correlation between genotype and phenotype is rarely present. In
large part, this relates to recessive inheritance and the
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complex. The most common gene mutation in the γ-sarcoglycan
in LGMD 2C is c.525delT, and this mutation has been described
in muscular dystrophy patients worldwide. Because this
mutation is commonly noted in linkage disequilibrium with
neighboring markers, it is thought to be evolutionarily aged. The
age of this mutation may have allowed for the development of
modifiers since this single mutation is associated with striking
phenotypic variability [8]. In this report, affected members from
three families have severe symptoms while those from the fourth
family were largely spared. The patients were all from Brazil
arguing against large environmental or diet differences. Since
this early report, this phenotypic variability has been confirmed
with this mutation [9]. The severity of phenotype did not strictly
correlate with presence or absence of the remaining, unmutated
sarcoglycan family members [9].
A common γ-sarcoglycan mutation, C283Y, occurs in the
Roma population throughout Europe [10], and this mutation
typically associates with a severe phenotype and an absence
of γ-sarcoglycan from the plasma membrane. In two sisters
with LGMD 2C, the G69R γ-sarcoglycan mutation was
identified on one chromosome and a large deletion in the
opposite γ-sarcoglycan gene [11]. The sisters had a severe
clinical presentation and required wheelchairs by age 12 years
old with markedly elevated serum creatine kinase levels.
Taken together we can hypothesize that the cysteine at amino
acid residue 283 and the glycine at residue 69 are highly
critical for proper γ-sarcoglycan expression since common to
each of these mutations is the loss of γ-sarcoglycan. C283 is
highly conserved and forms a conserved motif found at the
carboxyl-terminus of β- and δ-sarcoglycan and is thought to
contribute to the formation of intramolecular disulfide bridges
[12,13]. The loss of a disulfide bridge likely affects the
trafficking of γ-sarcoglycan to the plasma membrane.
Muscle biopsies can be helpful for determining phenotypic
severity. The degree that the unmutated sarcoglycan compo-
nents remain and traffic normally to the plasma membrane has
an inverse correlation with phenotypic severity, although
exceptions occur. For example, the severe mutation G69R
demonstrated only reduced α-sarcoglycan staining, indicating
that sarcoglycan subcomplex trafficking is not completely
disrupted, despite the severe phenotype [11]. In addition, the
C283Y mutation displays variable residual staining that does
not correlate with disease severity [10].
4. Merosin deficient congenital muscular dystrophy
Congenital Muscular Dystrophy (CMD) is present at birth
and arises from a subset of genetic defects. Mutations in the
gene encoding laminin α2, also known as merosin, lead to
CMD [14]. The DGC directly interacts with laminin α2 through
an interaction of dystroglycan. However, the phenotype from
laminin α2 gene mutations is phenotypically distinct from what
is seen with dystrophin or sarcoglycan gene mutations.
Furthermore, there is evidence to support that laminin α2
gene mutations produce pathology by a distinct mechanism in
that murine models support differences in membrane instabilityand levels of apoptosis [15–17]. The dy/dy model harbors a
large deletion in the laminin α2 gene and recapitulates many
aspects of CMD. A second spontaneous mutation in laminin α2
occurs in the dy2J/dy2J mice that have a smaller deletion and a
slightly milder phenotype than what is seen in the dy/dy mice.
At least two targeted disruptions have been generated at this
locus resulting in a similar phenotype of rapidly progressive
muscle weakness with paralysis affecting the hindlimbs
associated with spasticity [18,19].
5. Murine models and DGC modifiers
One striking discrepancy for dystrophin gene mutations is
noted when comparing the muscular dystrophy phenotype
between man and mice. The mdx mouse provides a useful
model for DMD in that a premature stop codon results in the
absence of full length dystrophin [20], and the histopathology in
the mdx mouse is similar to what is seen in DMD patients.
However, the loss of dystrophin does not result in a comparable
degree of physical impairment in mice as it does in boys with
dystrophin gene mutations. Without support, the lifespan of
DMD patients is less than one third normal while the lifespan of
mdx mice is shortened only modestly. Despite the functional
differences between the mdx mouse and boys with DMD, the
histopathology in the mdx mouse is a good reflection of a
particular dystrophin mutation. When dystrophin is engineered
to lack its actin binding domain and introduced transgenically
into mdx mice, the resultant animals have a mild Becker-like
phenotype [21]. Therefore, structure–function relationships can
be determined from these analyses supporting the role as the
precise dystrophin mutation itself as the major determinant of
phenotype. It has been suggested that the milder phenotype in
the mdxmouse may derive, in part, from the presence of genetic
modifiers that may now be present after decades of inbreeding
to support the line. Nearly all mdx colonies are maintained as
homozygous inbred lines, and therefore any genetic variation
that affects reproductive fitness will rapidly be assimilated into
the colony. Therefore, genetic modifiers that affect the
cardiovascular fitness are most likely to be maintained within
colonies. Consistent with this, the cardiac phenotype in the mdx
mouse is very mild compared to human DMD counterparts [22].
Mouse models of sarcoglycan gene mutations recapitulate
many aspects of the LGMD muscular dystrophy phenotype
including a more severe muscle and cardiac phenotype than
what is seen in the mdx mouse. In the case of γ-sarcoglycan
gene mutations, there is evidence to support the presence of
genetic modifiers. Mice lacking γ-sarcoglycan were engineered
by eliminating the exon that encodes the initiator methionine
and the transmembrane domain. This mutation results in a
complete absence of γ-sarcoglycan protein and produces partial
secondary reduction of the remaining, unmutated sarcoglycan
subunits, α, β and δ [23]. Sgcg null mice display a reduced
lifespan and develop cardiomyopathy that can manifest as
sudden death due to cardiac arrhythmias [23]. There is evidence
for coronary artery vascular spasm that develops as a
consequence of loss of sarcoglycan in cardiomyocytes. This
vascular smooth muscle cell-extrinsic mechanism can be
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cardiomyocytes of Sgcg null mice [24,25]. A second,
independent gene targeting using the same gene targeting
strategy for the γ-sarcoglycan gene was reported [26]. These
mice were generated on a similar mixed 129SVE and C57Bl6
background, but these mice displayed less lethality and more
muscle hypertrophy consistent with influence on the phenotype
by alternative genetic loci.
The allele generated by Hack et al. was bred heterozygously
through ten generations onto four different genetic background
strains to inquire whether genetic background can influence
phenotypic outcome in the muscular dystrophies [27]. For these
experiments, it is critical to maintain heterozygous breeding to
avoid selection through the breeding process. After breeding,
heterozygous mice were interbred and the histopathologic
phenotype was compared using two different assays. The first
assay measured uptake of Evans Blue Dye (EBD) into muscle.
Uptake of EBD has been noted in the mdx mouse but not in the
dy/dy mouse [15], and is similarly a feature of sarcoglycan gene
mutations. EBD uptake into muscle reflects plasma membrane
instability and is an indicator of the degree of myofiber damage
within a muscle. This quantitative analysis was conducted on
Sgcg nullmice and revealed that DBA 2J results in quantitatively
more EBD uptake than the Sgcg null allele bred into other
backgrounds. Similarly, quantitative analysis of EBD uptake
revealed that the Sgcg null allele in the 129/SVEMS+/J
background was least affected. A second distinct assay was
performed that analyzed the deposition of hydroxyproline into
the muscle. Fibrosis and ongoing replacement of the muscle by
connective tissue in muscular dystrophy can be measured by an
increase in hydroxyproline content. Using this analysis, we
found that, again, the Sgcg null allele in the DBA 2J background
contained the greatest hydroxyproline content indicating a moreFig. 2. Comparison of diaphragm muscles from Sgcg−/− mice on different genetic bac
of centrally placed nuclei, fiber size, fibrotic infiltrate, hypertrophy and hyperplasia. T
parameters; note, the marked pseudohypertrophy related to fibrofatty infiltration. Eisevere phenotype in this background. Similarly, hydroxyproline
content was less in Sgcg nullmice bred into the 129/SVEMS+/J
background consistent with a milder phenotype. We also
compared whether the same animals that displayed increased
EBD uptake were identical to those with increased collagen
content and fibrosis. However, regression analysis suggested no
correlation and was consistent with membrane damage being
independent from collagen deposition and fibrosis in muscular
dystrophy. An example of the varying histopathology associated
with the Sgcg null allele in the different background strains is
shown in Fig. 2. We further determined that activity levels were
not increased in DBA 2J mice excluding an increase in physical
activity as responsible for the enhanced muscular dystrophy
phenotype in the DBA 2J background. Through further breeding
and genetic mapping, genetic modifiers will be identified.
6. Dihybrid genetic crosses
Many modifier loci have been identified in murine models
through genetic breeding that uncovers synthetic relationships
between gene products (Table 2). These genetic modifiers may
encode proteins that have direct homology or other structural
similarity to dystrophin or the sarcoglycan complex. Alterna-
tively, these genetic modifiers may work in unrelated pathways
that function synergistically to enhance or ameliorate the
muscular dystrophy phenotype. Utrophin, a dystrophin homo-
log, is upregulated in DMD patients and in the muscle fibers of
mdx animals [28]. To demonstrate the functional overlap of
utrophin with dystrophin, it was shown that utrophin driven by
the skeletal α-actin promoter could rescue the phenotype of the
mdx mice [29]. Three independent transgenic lines were
generated and they rescued the phenotype in a dose dependent
manner. The transgenic mice had improved morphology, andkgrounds. Phenotypic variability is demonstrated through differences in number
he mutant mice on the DBA background have enhanced phenotype by all of these
ght-week-old diaphragms are shown, scale bar represents 100 μM.
Table 2
Modifier effects by functional interaction in mdx mice, unless otherwise noted
Function Implicated genes Mouse data Reference
Structural Utrophin Increased in regenerating fibers [122]
mdx/utr −/− worsens mdx phenotype [30]
Transgene aids mdx phenotype [29]
Integrin α7 Increased in regenerating fibers, mdx and sgcg [50]
Transgene aids mdx/utr −/− phenotype [39]
Itgα7−/−/sgcg worse phenotype [51]
Signaling IGF-I Signaling is increased in transgenic IGF-I, mdx mouse [61]
Necrosis IGF-I Necrosis is decreased in transgenic IGF-I, mdx mouse [61]
Immunity nNOS Decreased in mdx [40]
Transgene lessens mdx phenotype [44]
CD4+ T cells Antibody depletion lessens phenotype [47]
CD8+ T cells Antibody depletion lessens phenotype [47]
T cells mdx on nude mouse background lessens phenotype [48]
TNF Double knockouts tnf/mdx enhanced pathology [49]
Regeneration, and muscle formation Myostatin mstn−/−/mdx mice have reduced pathology [53]
IGF-I Transgene lessens mdx pathology by increasing regeneration [61]
1 mg/kg increased fatigue resistance in mdx [63]
ADAM12 Re-expressed in regenerating fibers [65]
Transgene lessens mdx phenotype [66]
Dysferlin Important during membrane fusion [4]
Calpain Role in muscle maturation [101]
Survival Bax Inactivation increased lifespan in Lama2−/− mice [69]
Bcl-2 Transgene increased lifespan in Lama2−/− mice [69]
ADAM12 Transgene lessens mdx cardiomyopathic phenotype [69]
Calpain 100 fold increase in apoptotic nuclei in LGMD 2A [98]
Fibrosis IGF-I Fibrosis is decreased in transgenic IGF-I mouse [61]
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Importantly, transgene expressed utrophin localized to the
sarcolemma and caused α-dystrobrevin, α-sarcoglycan and
syntrophin to relocalize to the sarcolemma. These experiments
form the basis of determining a mechanism to increase
endogenous utrophin expression as a therapy for DMD.
Further evidence to support the overlapping roles of utrophin
and dystrophin in muscle pathology is the observation that
double mutant mice lacking dystrophin and utrophin displayed
a much more severe phenotype [30,31]. The mdx/utrn−/− mice
have reduced life span and increased pathology, joint
contractures, weight loss and kyphosis. These data directly
demonstrate that utrophin upregulation compensates in the mdx
mouse, and increasing utrophin expression to higher levels is a
valid therapeutic strategy. The singly mutated utrn−/− mouse
display only minor neuromuscular junction defects and
negligible muscle pathology [32]. Importantly, utrophin over-
expression is not toxic to the remainder of the animal [33]. The
upregulation of utrophin can be post-translational in humans
and mice [34]; therefore therapies that stabilize the protein may
be beneficial to humans [35,36]. One caveat to this approach is
that no inverse correlation was found between amount of
utrophin over expression and disease progression in DMD and
BMD patients [37]. However, the limited sampling from muscle
biopsies and/or the degree of utrophin upregulation may
account for these negative findings.
In the 10 years since its generation the mdx/utr−/− mouse line
has been largely bred as mdx hemizygous or homozygous null
and utr+/−. When comparing the original phenotype with more
recent publications, a trend is quickly noticed. Longevityincreased from 4–14 weeks, to 4–20 weeks to most recently a
36-week maximum was observed [31,38,39]. Continual hemi-
zygous and sibling intercross breeding may lead to selection of
beneficial genetic modifiers and reduced phenotype and
increased longevity.
7. Nitric oxide synthase
Neuronal nitric oxide synthase (nNOS, and also known as
NOS1) is secondarily decreased from the plasma membrane in
DMD and the mdx mouse [40,41]. This displacement of nNOS
has been implicated in the degenerative process. However,
when double mutant mice (mdx/nNOS−/−) were compared to
mdx mice, no phenotypic modulation was detected [42,43]. Yet
when nNOS was introduced transgenically into the mdx
background, the muscular dystrophy phenotype was greatly
attenuated in both skeletal and cardiac muscle [44,45]. The
nNOS transgene restored NO levels to normal levels in mdx
animals from a reduction of 80% in non-transgenic mdx mice.
The transgenic mice had reduced pathology by histology, fiber
size variability, infiltrating macrophages, central nuclei, EBD
uptake, CK levels and MHC class II staining. The authors
convincingly argued that these benefits are due to a decrease of
inflammation and infiltrating macrophages. When macrophages
are depleted from mdx, there is a 75% reduction in injured
fibers. Furthermore, it was shown thatmdxmuscle macrophages
are cytotoxic to myofibers in vitro. The mdx/nNOS−/− mice did
not demonstrate an increase of utrophin or integrin α7 proteins,
lending further support that nitric oxide from the transgene is
inhibiting immune cells [46]. Despite no reduction of nNOS of
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specific nNOS partially rescues the cardiomyopathy associated
with dystrophin loss [45]. In particular, macrophage numbers,
heart rate variability, ECG abnormalities and fibrosis were
returned to normal levels.
Further evidence for immunopathology contributing to the
muscular dystrophy phenotype comes from T cell ablation
experiments. Antibody depletion of CD8+ or CD4+ T cells
early in disease reduces pathology of mdx mice [47]. CD4+ T
cell depletion reduced skeletal muscle pathology by 61%, and
CD8+ T cell depletion reduced skeletal muscle pathology by
75%. In addition, breeding mdx mice with T cell deficient nude
mice reduced fibrosis [48]. However, not all immune system
inhibition is beneficial to the mdx mouse. When tumor necrosis
factor null mice were bred to mdx mice the pathology became
enhanced and benefit was only observed in 8-week quadriceps
muscle [49].
8. Integrin
Increased expression in the major laminin-binding integrin
of mature muscle, integrin α, has been noted in both DMD
patients and mdx mice [50]. Based on this observation, it was
examined whether manipulation of integrin expression could
alter the muscular dystrophy phenotype in mouse models [39].
The rat α7 integrin chain was introduced into mdx/utr−/− mice
transgenically under the control of the muscle creatine kinase
promoter. The resultant transgenic animals demonstrated
reduced disease with enhanced longevity, mobility, and weight
maintenance and reduced kyphosis, joint contractures, mono-
nuclear cell infiltrate, and expression of fetal myosin heavy
chain. Therefore, overexpression of a specific component in the
actin-DGC-extracellular matrix complex compensated for
absence of another component. In support of these data are
observations from mice lacking both sarcoglycan and integrin
α7 [51]. As in the mdx mouse, there is an upregulation of
integrin α7 in sarcoglycan mutant muscle. Mice lacking both
γ-sarcoglycan and integrin α7 display a severe phenotype with
early lethality no animal survived beyond 1 month and, in
addition, there was significant prenatal lethality. The double
mutant mice had enhanced muscle degeneration determined by
EBD uptake while regeneration appeared intact. These results
indicate that the two major laminin receptors of muscle,
sarcoglycan–dystroglycan and integrin α7, are compensatory
transmembrane linkers. Additionally, these data demonstrate
that upregulation of integrin α7 is compensatory, and, like
utrophin upregulation, is a viable therapeutic target for treating
muscular dystrophy.
9. Myostatin
Myostatin is a TGFβ family member that is an inhibitor of
skeletal muscle growth [52]. Because the myostatin null mouse
(Mstn−/−) has an increased muscle mass due to hyperplasia and
hypertrophy, it was bred to the mdx mouse model to determine
its effect on muscular dystrophy [53]. The resultant mice had a
reduced severity of disease as measured by muscle weight, gripstrength, muscle fiber diameter, histology and hydroxyproline
content. These findings have translated closer to therapy in that
myostatin inhibitors also attenuate the mdx phenotype [54,55].
Although these results have been encouraging and lead to
human clinical trials, a second dihybrid cross was undertaken
which cautions against the positive results of the mdx/Mstn−/−
data. The same myostatin null mutation was bred onto the
laminin-deficient mice, dyW/dyW, a model for merosin deficient
CMD. In this cross, increased muscle regeneration and muscle
mass, due primarily to hyperplasia, were present. However, no
improvement of muscle pathology and an increase in pre-
weaning mortality was described [56]. The difference between
the two models may relate to intrinsic pathologic defects
between the two forms of muscular dystrophy. The more severe
phenotype of the dyW/dyW mice and/or the lack of tolerance for
decreased brown fat in the dyW/dyW mice may also contribute.
An alternative strategy that would directly test the contribution
of brown fat would utilize the cre-lox technology to eliminate
myostatin shortly after birth, beyond the window where brown
fat may be required [57]. Over-expression of a dominant
negative myostatin exclusively in differentiated muscles may
also reflect what can be achieved through pharmacologic
inhibition [58].
10. Insulin-like growth factor
Insulin like growth factor 1 (IGF1) regulates skeletal muscle
growth and regeneration [59,60]. Indeed, IGF-I overexpression
in mdx mice results in increased muscle fiber size and number
[61,62]. These transgenic mice also had normalized fibrosis as
measured by hydroxyproline content and increased total force,
but not specific force [61,63]. Functionally, mice receiving
1 mg/kg IGF-I for 8 weeks demonstrated resistance to fatigue in
ex vivo experiments [63]. This coincided with a phenotypic shift
to more fatigue-resistant and oxidative slow fibers.
11. ADAM12
ADAM (a disintegrin andmetalloprotease)-12 is expressed in
several tissues, and most predominantly in muscle during
embryogenesis [64]. Postnatally, ADAM12 is not normally
expressed in muscle. However, it is transiently re-expressed
during regeneration and it is believed to have a role in membrane
fusion [65]. ADAM12 null animals have intact muscle
regeneration, and constitutive ADAM12 overexpression in
adult muscle transgenically under the control of the muscle
creatine kinase promoter had beneficial effects upon mdx mice
[66]. The animals had less necrosis, inflammation, creatine
kinase and EBD uptake. Therefore, it is believed that ADAM12
aids muscle cell regeneration in the mdx mouse. Importantly,
beneficial affects were also seen in cardiac tissue, consistent with
a role for ADAM12 inmyocyte survival [66].When the identical
transgene expressing ADAM12 was bred into the more severely
effected dyW/dyW laminin α2 null animals, enhanced regenera-
tion was seen supported by increased numbers of central nuclei
and increased fetal myosin expression. However, the disease
progression was the same in transgenic and littermate control
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degeneration, inflammation, fibrosis and had reduced weight.
Interestingly, the overexpression of ADAM12 in the mdx
background caused an increase of both utrophin and integrin
α7 [68], while only utrophin was upregulated in the dyW/dyW
transgenic animals [67]. The muscle creatine kinase promoter
that drives expression in these experiments may also influence
the difference in outcome. This promoter is highly expressed
only in fully differentiated fibers, and these fibers may bemore at
risk in the dyW/dyW mice. Supporting this mechanism is that
expression of ADAM12 from the same integration event was
lower in dyW/dyW mice then in littermate controls [67].
12. Apoptosis
Reduction of apoptosis by Bax inactivation or Bcl-2
overexpression increases the life span of laminin-α2 (merosin)
mutant mice [69, 70]. In addition, Bax inactivation increases the
weight of the animals through an increase in muscle mass and
reduces myofiber pathology. Apoptotic myonuclei have been
detected in DMD and mdx [71,72]. Despite this, muscle-
specific expression of Bcl-2 does not decrease pathology in mdx
mice [70].
13. Fukutin-related protein (FKRP) and dystroglycan
Enzymatic proteins that are thought to post-translationally
modify components of the DGC have been implicated in the
Congenital Muscular Dystrophies (CMDs). Fukuyama muscu-
lar dystrophy is caused by mutations in the gene encoding
fukutin [73], and congenital muscular dystrophy type 1C
(MDC1C) and LGMD-2I are both associated with distinct
mutations in the fukutin related protein (FKRP) [74,75]. FKRP
is thought to O-glycosylate proteins, and dystroglycan, a key
component of the DGC, is thought to be the primary defective
target in these disorders [76]. MDC1C is a severe muscular
dystrophy in which patients typically cannot stand. Alterna-
tively, the allelic LGMD-2I is less severe, although there is
phenotypic variability that can also affect the heart.
Dystroglycan is expressed on nearly all cells, but is essential
for normal muscle function [77]. Dystroglycan is produced
from a single gene, and after translation, it is cleaved into α- and
β-dystroglycan subunits. β-dystroglycan is only modified at N-
linked sugars, but α-dystroglycan is modified by both N- and O-
linked glycosylation. The subunits of dystroglycan assemble,
and at the membrane link dystrophin and cytoskeletal actin to
the extracellular matrix, thereby preserving sarcolemmal
integrity. Mice with a targeted deletion of dystroglycan are
embryonic lethal due to basement membrane defects in many
tissues [78]. Tissue specific gene deletions of dystroglycan
correlate with human diseases, demonstrating muscle pathology
and CNS involvement in the appropriate cre-expressing mouse
lines [77,79].
With the identification of muscular dystrophy causing
mutations in these post-translation modifying enzymes, a large
new group of proteins must be considered as potential modifiers.
Many proteins are involved in post-translational modificationsand mutational impairment of these may result in frank disease
as with FKRP, or may modify phenotype severity of other
mutations. In addition, FKRP itself is modified by other factors.
A specific mutation L276I is associated with a mild but variable
phenotype: age of onset can range from 5 to 25 years old, and
variable muscle groups are affected to differing levels [80].
14. Dysferlin
Mutations in the dysferlin gene produce Miyoshi myopathy
(MM), LGMD 2B and/or distal anterior compartment myopathy
[81,83]. MM is characterized as an early-adult onset, autosomal
recessive, distal muscular dystrophy with calf involvement and
elevated CK levels. LGMD 2B usually begins with proximal
muscle weakness and progresses more rapidly than MM. It has
been difficult to correlate genotype with phenotype in dysferlin
mutations [84], and the identical mutation can yield both MM
and LGMD-2B even within the same family. The presence of
the identical mutation associating with both mild and severe
forms of the disease argues for the presence of genetic modifier
loci [81,82]. In particular, the P791R mutation was found in a
large family that contained both MM and LGMD-2B patients
[82]. The LGMD-2B patients within this family presented with
rapidly progressing muscular dystrophy and required wheel-
chairs by their third decade. The MM patients were more mildly
affected. Interestingly, the amount of dysferlin protein retained
by these patients was independent of disease type and
progression [82].
Evidence is accumulating that the dysferlin family of proteins
function in membrane fusion events. The dysferlin gene contains
six C2 domains and a transmembrane domain at its carboxy-
terminus. A point mutation in the first C2A domain, V67D, was
reported in bothMM and LGMD 2B [85].When engineered into
dysferlin, this mutation was found to disrupt calcium sensitive
phospholipid binding [86]. The highly related family member
myoferlin is important in myoblast fusion to myotubes during
development and muscle regeneration [87]. The roles of
myoferlin, in myoblast fusion after cardiotoxin injury, implicate
it as a potentially interesting modifier and therapeutic target
[87,88]. Supporting this, myoferlin is increased in response to a
number of muscular dystrophies [89].
There is evidence from animal models to support the
existence of genetic modifiers of muscular dystrophy produced
by dysferlin gene mutations. Four separate dysferlin null
animals have been described. The first mutation in the murine
dysferlin gene was described in the SJL strain [90]. The SJL
strain is highly inbred and is a model for experimental
autoimmune encephalitis. Analysis of the locus indicated a
splice site mutation of the dysferlin locus and the loss of a 171
base pair exon. This exon is in frame but is reported to decrease
the level of dysferlin expression [91]. Two additional dysferlin
mutant models were described and compared [92]. In this work,
the authors describe a second spontaneous mutation in the A/J
line and compared its phenotype to a targeted deletion of the
same exon implicated in the SJL mice. The mutation in the A/J
mice was from a retrotransposon insertion that affects mRNA
and protein expression. This insertion was thought to have
Fig. 3. Comparison of fibrosis, fatty infiltrate and regeneration in A/J mice, a model for dysferlin mutations and LGMD 2B, and Sgcd−/−, a model for LGMD 2F. The
dysferlin null animals have increased fibro-fatty infiltrate and centrally placed nuclei compared to control mice. However, A/J mice have much milder histopathology
compared to Sgcd−/−mice animals. The A/Jmice have been maintained as an inbred strain and may have acquired genetic modifiers that attenuate the phenotype. Bars
are 100 μm.
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maintenance of this as an inbred strain has resulted in a milder
phenotype than the engineered mutation. An example of the
milder histopathology is seen in Fig. 3 and compared to the
phenotype in mice lacking δ-sarcoglycan. The muscular pathol-
ogy in these three lines is similar with the same muscles being
progressively affected. However, the A/J strain has a delayed
onset of disease and decreased EBD uptake. Because both these
lines are null for dysferlin, by immunoblot and mRNA,
differences of phenotype do not result from different mutations
or residual protein production. The SJL mice clearly contain a
divergent genotype as they are aggressive, susceptible to
autoimmune disease, B-cell lymphomas, and blind by weaning
[93–96]. Lastly, Bansal et al. reported a targeted disruption of
dysferlin and identified a defect in membrane resealing [4].
15. Calpain
Calpain 3 is a calcium-activated protease, and mutations in
the gene encoding calpain 3 produce recessively inheritedmuscular dystrophy. Calpain 3 has a nuclear localization signal
and has been detected in myonuclei [97,98]. The molecular
mechanism whereby calpain 3-mutation causes LGMD-2A is
unknown, but several hypotheses explain the pathologic
mechanism. Calpain 3 cleaves filamin 3 (a cytoskeletal protein
that binds directly to the cytoplasmic tails of γ-sarcoglycan and
δ-sarcoglycan), ezrin, talin, fodrin and titin [99,100]. It has also
been shown that calpain 3 deficiency is associated with a
marked increase in apoptosis, where a 100 fold increase of
apoptotic nuclei are found in muscle biopsies from LGMD-2A
patients compared to other genetic forms of muscular dystrophy
[98]. As an alternative but not mutually exclusive hypothesis,
calpain 3 also has a role in muscle maturation and sarcomere
remodeling [101].
Patients with calpain 3 mutations present with variable
clinical phenotypes. There is a large range in age of onset,
serum creatine kinase levels are usually elevated, but not always
[102]. de Paula et al. performed a large study of calpain 3
mutations to analyze genotype phenotype correlations [103]. As
expected, missense mutations usually cause milder disease than
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mutations was 21 years while the average for nonsense and
frame-shift mutations was 11.5 years. Similarly, wheelchair
requirement was greater for frame-shift mutations [104]. The
severity of disease loosely correlated with calpain deficiency by
immunoblot [103].
Variable phenotypes for identical mutations have also been
reported for LGMD-2A [103,105]. In an analysis of 20 patients
with the same mutation, age of onset and clinical disease
progressionwere highly variable [103]. The earliest diagnosiswas
at 2 years of age, while the oldest was 15 years old. Furthermore,
in a single family three siblings were wheelchair bound at 13,
while other siblings and cousins were onlymildly affected in their
twenties. Of particular note within LGMD-2A, female patients
have a better prognosis then their male counterparts [103,106].
The reason for this trend is as yet unknown, but the factor(s)
mediating the effect would be modifiers worth future investiga-
tion for possible therapeutic intervention sites.
Calpain 3 null mice were generated and develop a
progressive and mild muscular dystrophy with increasing CK
values, histopathology, myonuclei apoptosis and Evan's blue
dye uptake [107]. The histopathology revealed that muscle
groups were differentially affected. The authors also compared
pure 129Sv mice to C57BL/6/129Sv hybrid mice. The hybrid
animals displayed a slower progressing disease when analyzed
with histopathology.
16. Lamin A/C
Mutations in the gene encoding lamins A and C (LMNA)
produce an array of phenotypes including Emery–Dreifuss MD
(EDMD), LGMD-1B, Hutchinson–Gilford progeria syndrome,
familial partial lipodystrophy, dilated cardiomyopathy, manidi-
bulosacral dysplasia and others [108]. EDMD, both dominant
and recessive, are characterized by early contractures of the
elbows, Achilles tendons and neck and a slow progression of
muscle weakness. EDMD also involves dilated cardiomyopathy
and conduction abnormalities. LGMD-1B patients present with
proximal muscular dystrophy and weakening, and dilated
cardiomyopathy with conduction abnormalities. Hutchinson–
Guilford progeria is evident within 2 years of birth and is
characterized by short stature, alopecia with small facial
features. As the disease progresses, cardiovascular issues arise.
Hutchinson–Guilford progeria is accelerated aging at a rate six
to eight times faster then normal. The partial lipodystrophies are
usually diagnosed at puberty as a decrease of subcutaneous fat
from the upper and lower extremities; type II diabetes usually
follows by age 20.
Two nonexclusive mechanisms have been developed to
explain the divergent phenotypes seen with LMNA gene
mutations [109]. The first hypothesis emphasizes lamin A/C's
role in nuclear membrane structural integrity. The second
pathogenic mechanism implicates lamin A/C's ability to
modulate nuclear functions such as DNA replication, gene
expression and nuclear export. The structural integrity of nuclei
containing mutated lamin has been demonstrated in vitro and ex
vivo. Cells expressing mutant lamin have severe nuclearabnormalities; these abnormalities include mislocalization of
other inner-nuclear membrane proteins such as emerin
[110,111]. Likewise, fibroblasts taken from patients with
lipodystrophy also have severe nuclear abnormalities and
demonstrated increased susceptibility to stress [112]. Mice
deficient for lamin A/C display similar nuclear abnormalities as
those seen in primary patient fibroblasts [113]. The gene
expression hypothesis has been investigated in lamin A/C
deleted mice that display impressive chromatin changes and
possible defects in gene expression [114].
Although attempts have been made at identifying functional
domains within the Lamin A/C protein, no clear correlation
exists between mutated residues or mutated protein domains
and disease phenotype [115]. A difficult step in attempting this
genotype/phenotype correlation with lamin A/C is that
mutation of this ubiquitously expressed protein causes tissue-
specific diseases [116]. A further confounding consideration is
the difference between human and mouse mutations with
respect to lamin A/C diseases. In an effort to generate mice
with autosomal dominant EDMD, a heterozygous LMNA
dominant mutations was engineered [117]. Surprisingly no
heterozygote phenotype existed. Homozygous animals dis-
played Hutchinson–Guilford progeria instead of a muscular
dystrophy.
Identical mutations within lamin A/C gene cause vastly
different phenotypes. Variations are found in age of onset,
cardiac involvement, muscle group involvement, CK elevation
and other parameters [75]. In addition, penetrance is different
even within a single family: ranging from silent to completely
penetrant [118].
17. Conclusions and perspectives
The variable phenotype in the muscular dystrophies presents
complications for physicians and genetic counselors seeking to
advise patients and families with genetic mutations. Some
phenotypic variability can reliably be predicted from genotype–
phenotype correlations. In general dystrophin gene mutations
are predictive of outcome, although exceptions are present.
Additional examples are seen in some LGMD patients, although
in general structure–function relationships have been less
evident in LGMD than in DMD. Despite having some clear
genotype–phenotype relationships, there is an increasing body
of evidence indicating that modifier genes greatly affect disease
phenotype. The evidence stems from both human and murine
analyses.
Many different single genes have been shown to alter the
pathogenesis of muscular dystrophy in the mdx mouse. The
functions of these proteins fall into one or more categories:
structural, signaling, reduction of necrosis, reduction of immune
infiltration, regeneration promotion, and survival factors (Table
2). Some of the protein products of the manipulated genes may
compensate structurally such as utrophin and integrin-α7.
Others appear to re-establish important signaling cascades
including nNOS and ADAM12. Others, such as calpastatin,
reduce necrosis. Manipulation of the immune system is also an
effective modifier, although one that is genetically complex.
225A. Heydemann et al. / Biochimica et Biophysica Acta 1772 (2007) 216–228Other factors serve to promote regeneration and increase muscle
mass, and these genes include myostatin inhibition and IGF1.
The illumination of these many pathways will aid in under-
standing disease progression and prognosis and present novel
targets for therapy.
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